You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202331 - 202340 of 207728 results
  1. Validation of a non invasive technology to measure bilirubin in newborns

    SBC: BiliCam LLC            Topic: NICHD

    Project Summary Neonatal jaundice or hyperbilirubinemia is an almost ubiquitous condition in newborn infants In very rare circumstances if an infant with signficant hyperbilirubinemia is undetected kernicterus a devastating and permanent neurologic condition can develop Still rare but much more frequently a neonate with significant jaundice is not identified until the bilirubin level is ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a novel, adjuvant implant for post-metastatic skeletal lesions

    SBC: ZETAGEN THERAPEUTICS, INC.            Topic: 102

    Project SummaryBone growth is critical to a favorable prognosis in thebreast cancer patients that have skeletal metastasesor approximatelypatients per year in the USLytic lesionsor voids in the boneresult from local bone destruction caused by tumor cell directedosteoclastic bone re absorption and lead to pathologic fracture and increased patient morbiditySurgical intervention is necessary to preve ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Validation of a Novel Automated Seizure Detection and EEG Trending System for Con

    SBC: Optima Neuroscience, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Increased recognition of the incidence of nonconvulsive seizures (NCSs) in critically ill patients has led to a growing demand for continuous EEG monitoring in Intensive Care Units (ICUs). However, one of the biggest challenges to the expanding use of continuous EEG monitoring in the ICU lies in the difficulty of providing a timely review of clinical data by EE ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer's-Disease-Related Dementias

    SBC: IMAGINOSTICS, INC            Topic: R

    PROJECT SUMMARY Alzheimer’s disease (AD), a degenerative brain disorder, is responsible for 60-70% of all dementia. Currently no reliable biomarkers exist for precision-medicine-level, single-patient diagnostics for the early detection of Alzheimer’s disease and related dementias (AD/ADRD). Imaginostics proposes to clinically valdiate novel magnetic resonance imaging (MRI)-based proprietary bi ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease

    SBC: THERALOGICS, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs still exist. Activation of NF??B transcription factors are central events in the initiation and perpetuation of chronic inflammation in IBD. TheraLogics, Inc., have been at the forefront of NF??B researc ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of a Novel NF-KB Inhibitor in Murine IBD

    SBC: THERALOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for these disorders have non-specifically suppressed the immune response to inhibit intestinal inflammation. Specific understanding of immune pathways has led to the development of TNF blockade as a treatme ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Validation of a Novel NF-KB Inhibitor in Murine IBD

    SBC: THERALOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for these disorders have non-specifically suppressed the immune response to inhibit intestinal inflammation. Specific understanding of immune pathways has led to the development of TNF blockade as a treatme ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. VALIDATION OF A NOVEL SARCOMERIC HIGH THROUGHPUT ASSAY

    SBC: CYTOKINETICS, INC.            Topic: N/A

    DESCRIPTION: (Investigator's abstract) The US. heart failure population numbers approximately 5 million and is growing. Despite treatment with current medical therapy, many patients remain symptomatic and require frequent hospitalization, placing an enormous burden on our health care system. Currently, the most ineffective arm of medical therapy are agents that modulate ...

    SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. Validation of a novel, small molecule-based osteoinductive lumbar fusion implant

    SBC: ZETAGEN THERAPEUTICS, INC.            Topic: NIAMS

    Project SummaryOverlumbar spine fusions are performed each year in the USwhich result from a number of spinal pathologies that include degenerative lumbar slipslumbar stenosisdegenerative scoliosis and fracturesIn the USan aging populationhigh smoking ratesincreasing obesityand longer life expectancy together will increase the number of lumbar spinal fusion procedures byover the next decadeSuccess ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government